How do I set a price alert for ALKS?

To set a ALKS price alert on Stock Alarm Pro, navigate to the ALKS quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for ALKS?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for ALKS. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for Alkermes?

Stock Alarm Pro supports over 125 trigger types for ALKS: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about ALKS price changes?

ALKS alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for ALKS alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for ALKS and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

Alkermes (ALKS) Price Alerts

Demo Sign up Log In

Alkermes plc(ALKS)

NASDAQClosing price · checked 4:31 PM ESTAbout this dataData status

$46.47▲0.30 (0.65%)

After Hours:$46.47+0.00 (+0.00%)

WatchlistChart Studio

ALKS(ALKS)

ALKS

Nasdaq below the 200-day average · S&P 500, Russell 2000 below the 50-day average

Market overview →Overview →

Explore More

ALKS Financial Metrics

Explore 130+ historical metrics & ratios

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.

ALKS Fundamentals

Annual and trailing 12-month values

All metrics →All fundamentals →

ALKS News

All news →

About

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

Website

www.alkermes.com ↗

Leadership (11)

Blair C. JacksonPresident, CEO & Director

Christian Todd NicholsSenior Vice President & Chief Commercial Officer

David Joseph GaffinExecutive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary

Declan O'ConnorSenior Vice President of Operations and Environment, Health & Safety

Peter NormanSVP of Policy, Government & Community Relations

Samuel J. ParisiInterim Principal Accounting Officer & Vice President of Finance

Stephen SchiavoSenior Vice President & Chief Human Resources Officer

Tom SkoffSVP & Chief Information Officer

Sandra CoombsSenior Vice President of Corporate Affairs & Investor Relations

Craig C. HopkinsonExecutive Vice President of Research & Development and Chief Medical Officer

Joshua ReedSenior Vice President & Chief Financial Officer

About

Outlook

AI Stock RatingLoading rating…15 analystsBuy$56.00+20.5%

TrendUptrend6.3% above 50-day

Key Metrics

TTMAll charts →

Select a linked metric to explore its chart.

Market Cap$7.80B Revenue TTM$1.75B

Rev Growth FY26E+23.8%

Rev Growth YoY+15.3%Price / Sales4.4x P/E (TTM)48.9x

Fwd P/E FY27E80.6x

Net Income TTM-$351.0K Free Cash Flow$227.37M Gross Margin82.9%Operating Margin3.7%Net Margin-0.0%Return on Equity-0.0%

Return on Assets-0.0%

Debt / Equity (MRQ)0.84 Current Ratio (MRQ)2.42 EPS TTM$-0.00

All ALKS metrics →Financial statements →

Trading snapshot

Price & range

Prev Close

46.17

Open

45.67

Day Range45.35 – 46.57

45.35

46.57

52W Range27.00 – 55.67

27.00

55.67

68% of range

50-Day MA

43.71(+6.3%)

200-Day MA

40.82(+13.8%)

Volume & size

Avg Volume

1.9M

Valuation & risk

P/E (TTM)

48.9x

Premium valuation

EPS (TTM)

—

Div Yield (TTM)

No dividend

Beta

0.57

Low vol

Momentum

RSI (14)

60

Bullish momentum

Upcoming Events

EEarnings Report

In 106 days

Feb 24

Explore More

S&P 500 Sector Leaderboards

Fundamental Metric Rankings

ALKS Fundamentals

ALKS News

About

Leadership (11)

About

Upcoming Events

Outlook

About

Leadership (11)

Key Metrics

ALKS Fundamentals